Journal
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
Volume 33, Issue 6, Pages 637-645Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/COC.0b013e3181b8afcf
Keywords
triple-negative; breast cancer; review
Categories
Funding
- Pfizer Inc.
Ask authors/readers for more resources
This review describes the pathology, prognosis, current treatment options, and future directions for the management of patients with triple-negative breast cancer. Triple-negative tumors lack expression of estrogen and progesterone receptors, and HER2. The subtype comprises some 15% of all breast cancers, with tumors of a typically larger size and higher grade. Clinically, triple-negative breast cancer has a relatively high rate of recurrence and distant metastasis, and poor overall survival. The standard of care is chemotherapy, although recent research suggests a sound rationale for the use of targeted agents with antitumor and/or antiangiogenic activity such as receptor tyrosine kinase inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available